Identifying Resistance Mechanisms Of Targeted BRAF Inhibitors In Metastatic Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$379,015.00
Summary
Late-stage melanoma is an aggressive skin cancer for which traditional treatment strategies such as chemotherapy are ineffective. Recently, a new class of targeted drugs (BRAF inhibitors) has become the standard of care for a subset of melanoma patients; however, long term treatment success is complicated by drug resistance. This study will identify the causes of resistance with the purpose to improve targeted drug strategies and increase survival rates for late-stage melanoma patients.
Genetic And Environmental Epidemiology Of Early-onset Melanoma In The Australian Melanoma Family Study
Funder
National Health and Medical Research Council
Funding Amount
$412,210.00
Summary
This project will investigate the genetic and environmental causes of melanoma, especially melanoma developing under the age of 40 in Australian families. This project will help to identify which people are at greatest risk of developing melanoma, by identifying the genes involved in melanoma development and the contribution of environmental and lifestyle factors to the disease. We will also determine how much hereditary factors contribute to melanoma risk.
Targeting Survival Pathways To Overcome The Resistance Of Human Melanoma To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$332,123.00
Summary
Melanoma is a major Australian health problem. This is believed to be due to resistance of melanoma cells to cell death associated with inappropriate activation of survival signalling pathways. My previous studies have provided a number of insights into resistance mechanisms of melanoma cells to apoptosis. I wish to understand more fully the molecular basis of the survival signalling pathways, and to identify new therapeutic targets for overcoming resistance of melanoma to treatment.
Feasibility Of Implementing Precision Medicine For The Treatment Of Metastatic Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Melanoma is the most aggressive form of skin cancer, accounting for 75% of skin cancer deaths in Australia. When it progresses to stage IV disease, patient prognosis is poor, with less than 10% of cases surviving to 5 years. The goal of this project is to determine whether drugs currently used to treat different diseases could also be used to treat melanoma patients and improve their survival, particularly those that do not respond in current clinical trials.
The Mutational Landscape Of Melanoma In Adolescents And Young Adults
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Melanoma is the most common cause of cancer mortality in 20-34 year olds and many traditional treatments, chemotherapy and radiotherapy cause tremendous long-term damage to growing bodies. Fortunately new drugs that target the genetic mutations are proving effective. Unfortunately, the genomic mutation specific to young melanoma patients are unknown. This study aims to characterising the genomic mutations of young melanoma patients, leading to the discovery of innovative treatment options.
Treating Metastatic Melanoma With Stereotactic Ablative Body Radiotherapy And IMmune Pathway ACTivation (SABR-IMPACT)
Funder
National Health and Medical Research Council
Funding Amount
$185,445.00
Summary
Metastatic melanoma has historically had extremely poor survival. Drugs that activate the immune system provide some hope, and in the minority who respond survival beyond 10 years is possible. Radiotherapy causes local tumour death resulting in antigen exposure and systemic effects that may also stimulate the immune system. The combination of radiotherapy and immune activating drugs may be synergistic and result in improved survival for a greater proportion of patients.